diagnosis

Dr. Josh Sasine is a hematologist and oncologist at UCLA specializing in the treatment of hematologic malignancies, including hematopoietic stem cell transplantation (bone marrow transplantation), cellular therapy, and clinical trials of novel therapeutics. He is the Director of the Chimeric Antigen Receptor T-Cell (CAR T) Program. He treats patients with blood and bone marrow disorders such as leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, amyloidosis, aplastic anemia, Waldenstrom Macroglobulinemia, polycythemia vera, primary myelofibrosis, paroxysmal nocturnal hemoglobinuria

Dr. David Sallman is an Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center. Dr. Sallman’s clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). Dr. Sallman earned his MD degree from the University of South Florida College of Medicine. He completed an Internal Medicine Residency at Massachusetts General Hospital and, most recently, a Hematology/Oncology Fellowship at Moffitt Cancer Center. His research interests focus on the development of novel, targeted therapeutic strategies (Phase I and

Dr. Patel is an Assistant Professor at the University of Nebraska Medical Center. His reasearch interests include: Hematopoietic stem cell transplantation; alternative donors transplant including umbilical cord blood, transplantation of malignant and non-malignant disease.

Dr. Meyers was born and raised in rural Northern California and traveled around the country during her medical training. She developed an interest in hematology and oncology during medical school, and pursued a fellowship in that field after her internal medicine residency. While at the University of Utah, she performed laboratory research on bone marrow failure syndromes, with a focus on paroxysmal nocturnal hemoglobinuria. Her research continues at OHSU, and she currently has government and private foundation support to study the genetic changes that lead to bone marrow dysfunction and

Ruben A. Mesa, MD, FACP, is the president and executive director of Atrium Health Levine Cancer and Atrium Health Wake Forest Baptist Comprehensive Cancer Center. He also serves as vice dean for cancer programs and professor of medicine at Wake Forest University School of Medicine. In his roles, Dr. Mesa oversees all efforts related to cancer practice, research and education across the Atrium Health system. Dr. Mesa is an international expert in hematologic cancers. He has dedicated his life's work to research and drug development for myeloproliferative neoplasms (MPNs), a group of chronic

Lucy A. Godley, MD, PhD, is an expert in the care and treatment of patients with diseases of the bone marrow, including leukemias, lymphomas and multiple myeloma. She also cares for patients undergoing stem cell transplantation and patients with benign hematologic conditions.